{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:15:57Z","timestamp":1781554557134,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.chest.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T06:22:51Z","timestamp":1726899771000},"page":"772-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mortality and Health Outcomes Among Patients With Sarcoidosis Treated With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5857-884X","authenticated-orcid":false,"given":"Joseph","family":"Fares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"El Fadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9288-5093","authenticated-orcid":false,"given":"Joy","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5319-912X","authenticated-orcid":false,"given":"Jianxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-2221","authenticated-orcid":false,"given":"Giorgos","family":"Loizidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4615-4956","authenticated-orcid":false,"given":"Ross","family":"Summer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.chest.2024.09.009_bib1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2024.09.009_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.chest.2024.09.009_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.537382","article-title":"Sarcoidosis epidemiology: race matters","volume":"11","author":"Hena","year":"2020","journal-title":"Front Immunol"},{"issue":"suppl 6","key":"10.1016\/j.chest.2024.09.009_bib4","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1513\/AnnalsATS.201707-564OT","article-title":"Disease burden and variability in sarcoidosis","volume":"14","author":"Gerke","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.chest.2024.09.009_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"218","key":"10.1016\/j.chest.2024.09.009_bib6","first-page":"253","article-title":"Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy","volume":"55","author":"Ainslie","year":"1985","journal-title":"Q\u00a0J Med"},{"issue":"3","key":"10.1016\/j.chest.2024.09.009_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1378\/chest.107.3.706","article-title":"Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD","volume":"107","author":"Brice","year":"1995","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2024.09.009_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0002-9343(75)90395-2","article-title":"Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis","volume":"59","author":"Lieberman","year":"1975","journal-title":"Am J Med"},{"key":"10.1016\/j.chest.2024.09.009_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1749-6632.1976.tb47061.x","article-title":"The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis","volume":"278","author":"Lieberman","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.chest.2024.09.009_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.chest.2024.09.009_bib11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/j.2040-4603.2014.tb00567.x","article-title":"Classical renin-angiotensin system in kidney physiology","volume":"4","author":"Sparks","year":"2014","journal-title":"Compr Physiol"},{"issue":"12","key":"10.1016\/j.chest.2024.09.009_bib12","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1073\/pnas.76.12.6646","article-title":"Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas","volume":"76","author":"Silverstein","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.chest.2024.09.009_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1164\/rccm.202402-0265OC","article-title":"The renin-angiotensin-aldosterone system regulates sarcoidosis granulomatous inflammation","volume":"210","author":"Crouser","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.09.009_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5005\/ijcdas-55-2-105","article-title":"Angiotensin-converting enzyme inhibitors in the treatment of sarcoidosis and association with ACE gene polymorphism: case series","volume":"55","author":"Kaura","year":"2013","journal-title":"Indian J Chest Dis Allied Sci"},{"issue":"2","key":"10.1016\/j.chest.2024.09.009_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2004.05768.x","article-title":"Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors","volume":"150","author":"Mizuno","year":"2004","journal-title":"Br J Dermatol"},{"issue":"23","key":"10.1016\/j.chest.2024.09.009_bib16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.chest.2024.09.009_bib17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.chest.2024.09.009_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1253\/circj.CJ-19-0782","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease\u2014propensity score matching analysis","volume":"84","author":"Kim","year":"2019","journal-title":"Circ J"},{"issue":"25","key":"10.1016\/j.chest.2024.09.009_bib19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2024.09.009_bib20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2024.09.009_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.chest.2024.09.009_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/phar.2677","article-title":"A\u00a0propensity score-matching analysis of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker exposure on in-hospital mortality in patients with acute respiratory failure","volume":"42","author":"Fang","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.chest.2024.09.009_bib23","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/jch.14329","article-title":"Influence of angiotensin converting enzyme inhibitors\/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: a systemic review and meta-analysis","volume":"23","author":"Jia","year":"2021","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"2","key":"10.1016\/j.chest.2024.09.009_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/HYPERTENSIONAHA.119.13197","article-title":"Effect of Renin-angiotensin-aldosterone system inhibitors on short-term mortality after sepsis: a population-based cohort study","volume":"75","author":"Hsu","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.chest.2024.09.009_bib25","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.chest.2024.09.009_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1053\/snep.2001.26792","article-title":"New insights into actions of the renin-angiotensin system in the kidney: concentrating on the Ang II receptors and the newly described Ang-(1-7) and its receptor","volume":"21","author":"Arima","year":"2001","journal-title":"Semin Nephrol"},{"issue":"6","key":"10.1016\/j.chest.2024.09.009_bib27","article-title":"Ang-(1-7) attenuates podocyte injury induced by high glucose in\u00a0vitro","volume":"67","author":"Lu","year":"2023","journal-title":"Arch\u00a0Endocrinol Metab"},{"key":"10.1016\/j.chest.2024.09.009_bib28","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2147\/JIR.S307801","article-title":"The ACE2-Ang-(1-7)-Mas axis modulates M1\/M2 macrophage polarization to relieve CLP-induced inflammation via TLR4-mediated NF-small ka, cyrillicb and MAPK pathways","volume":"14","author":"Pan","year":"2021","journal-title":"J\u00a0Inflamm Res"},{"key":"10.1016\/j.chest.2024.09.009_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176233","article-title":"Ang-(1-7)\/Mas axis ameliorates bleomycin-induced pulmonary fibrosis in mice via restoration of Nox4-Nrf2 redox homeostasis","volume":"962","author":"Sheng","year":"2024","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.chest.2024.09.009_bib30","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1007\/s11033-021-06447-1","article-title":"Ang(1-7) exerts Nrf2-mediated neuroprotection against amyloid beta-induced cognitive deficits in rodents","volume":"48","author":"Varshney","year":"2021","journal-title":"Mol Biol Rep"},{"issue":"25","key":"10.1016\/j.chest.2024.09.009_bib31","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199606203342507","article-title":"Angiotensin receptors and their antagonists","volume":"334","author":"Goodfriend","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"1 suppl 1","key":"10.1016\/j.chest.2024.09.009_bib32","first-page":"163","article-title":"Receptors for angiotensin I and II","volume":"27","author":"Goodfriend","year":"1970","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.chest.2024.09.009_bib33","first-page":"111","article-title":"Angiotensin receptors: structure, function, signaling and clinical applications","volume":"1","author":"Singh","year":"2016","journal-title":"J Cell Signal"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224052656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224052656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:13:07Z","timestamp":1749859987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224052656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0012369224052656"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.09.009","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality and Health Outcomes Among Patients With Sarcoidosis Treated With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}